Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-25 @ 11:56 PM
Study NCT ID:
NCT00437294
Status:
TERMINATED
Last Update Posted:
2020-08-10
First Post:
2007-02-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-03
Start Date Type:
None
Primary Completion Date:
2009-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-03
Completion Date Type:
ACTUAL
First Submit Date:
2007-02-16
First Submit QC Date:
None
Study First Post Date:
2007-02-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-06-09
Results First Submit QC Date:
None
Results First Post Date:
2020-08-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2010-02-18
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2020-07-20
Last Update Post Date:
2020-08-10
Last Update Post Date Type:
ACTUAL